Insmed (INSM) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
United Therapeutics (UTHR) has outperformed Insmed (INSM) over the past year, gaining 19.3% versus a loss of 37.3%. Over five years, INSM leads with a +284.1% price change compared with +191.3% for UTHR. United Therapeutics is the larger company by market cap ($22.84 billion vs $21.40 billion), about 1.1 times the size, while Insmed is growing revenue faster (+66.7% vs +10.6%).
On valuation, United Therapeutics trades at a lower forward P/E (17.0x vs 126.1x for Insmed). United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus -210.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INSM | UTHR |
|---|---|---|
| Share price | $98.01 | $532.42 |
| Market cap | $21.40B | $22.84B |
| 1-day change | -3.67% | -2.31% |
| YTD return | -41.54% | +11.85% |
| 1-year return | -37.32% | +19.30% |
| 5-year return | +284.07% | +191.33% |
| P/E ratio (TTM) | — | 19.07 |
| Forward P/E | 126.07 | 17.03 |
| EPS (TTM) | $-4.10 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $606.42M | $3.18B |
| Revenue growth (YoY) | +66.73% | +10.61% |
| Net income (latest FY) | $-1.28B | $1.33B |
| Gross margin | 79.73% | 87.92% |
| Operating margin | -205.59% | 46.89% |
| Net margin | -210.54% | 41.94% |
| 52-week high | $212.75 | $609.35 |
| 52-week low | $90.39 | $409.07 |
| Distance from 52-week high | -53.93% | -12.62% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +101.75% | +22.02% |
| Average volume | 2.57M | 655.10K |
| Shares outstanding | 218.38M | 42.89M |
| Employees | 1,664 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTHR has outperformed INSM by 56.6 percentage points over the past year.
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus -210.5 cents for Insmed.
- Insmed grew revenue faster in its latest fiscal year (+66.73% vs +10.61%).
About Insmed
INSM stock →Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,664 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
INSM vs UTHR FAQ
Which is bigger, Insmed or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $22.84B compared with $21.40B for Insmed (INSM).
Which stock has performed better over the past year, INSM or UTHR?
UTHR returned +19.30% over the past 12 months, compared with -37.32% for INSM (price return, excluding dividends). Past performance does not predict future results.
Are Insmed and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.